Jun 03, 2024

DEP® cabazitaxel presentation at ASCO 2024 Annual Meeting (ASX Announcement)

Melbourne, Australia; 3 June 2024: Starpharma (ASX: SPL, OTCQX: SPHRY) today provides a copy of the DEP® cabazitaxel presentation that was delivered at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago, US. The presentation was part of an oral abstract session showcasing the final results of the DEP® cabazitaxel Phase 1/2 clinical trial.

The ASCO Meeting is the most comprehensive gathering of oncology clinicians, researchers, and pharmaceutical companies in the world. It provides a platform to hear the latest breakthroughs and advancements in cancer treatment. Only a small proportion of submitted abstracts are accepted for presentation at the ASCO Annual Meeting. This year, fewer than 4% of these accepted abstracts were designated for full or rapid oral presentation.

It is a significant achievement that both DEP® cabazitaxel and DEP® irinotecan abstracts were selected for oral presentation at the ASCO Meeting, a demonstration of the quality and potential clinical impact of the findings.

The DEP® cabazitaxel ASCO Meeting abstract (#3004) has been published in the Journal of Clinical Oncology (JCO) (Volume 42, Number 16)[1]. Professor James Spicer, MBBS FRCP PhD, professor of experimental cancer medicine at King’s College London, consultant in medical oncology, and Principal Investigator of the DEP® cabazitaxel trial at Guy’s and St Thomas’ NHS Foundation Trust in London, delivered the presentation over the weekend.

View/download the ASX Announcement: DEP® cabazitaxel presentation at ASCO 2024 Annual Meeting.

[1] https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.3004

 This contains certain forward-looking statements.